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BAFF = B-cell-activating factor; SLE = systemic lupus erythematosus; TACI = transmembrane activator and CAML-interactor; TNF = tumor necro-
sis factor; TRAF = TNF-receptor-associated factors.
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Introduction
B cells are believed to be central to the pathogenesis of
SLE. Specific patterns of autoantibodies are characteristi-
cally detected in lupus; in addition, a direct pathogenic
role of these autoantibodies has been convincingly
demonstrated for at least some, such as anti-dsDNA, anti-
Ro, and anti-cardiolipin antibodies. Besides secreting
pathogenic antibodies, recent studies have shed impor-
tant new light on the role of B cells in shaping the immune
repertoire, thereby pointing to new ways in which B cells
may contribute to the pathogenesis of lupus. In contrast to
mice deficient in T-cell receptors, mice lacking B cells do
not develop M cells in the gut, suggesting that B cells are
involved in the organogenesis of gut-associated lymphoid
tissue [1]. Since M cells can function as professional
antigen-presenting cells, it was unexpected that B cells
play a ‘directing’ role during the development of these
cells. An important murine model for lupus is the
MRL-lpr/lpr mouse, characterized by Fas deficiency,
double negative T cells, autoantibodies, vasculitis, and
glomerulonephritis. Chan et al [2] showed that MRL-lpr/lpr
mice deficient in antibody secretion still develop nephritis
and vasculitis. This finding challenged the standard view
that the major contribution of B cells in promotion of
autoimmunity in murine lupus is by antibody production,
and led to the speculation that B cells may play a promot-
ing role as antigen-presenting cells in the course of the
disease. Chan et al suggested that their findings are con-
sistent with the presence of an amplification loop between
cognate B and T cells, resulting in an increase of memory
and effector T cells [2]. This latter interpretation is consis-
tent with a recent study by David Gray and colleagues [3]
demonstrating that TH cell memory depends on the pres-
ence of B cells but is clearly independent of the presenta-
tion of peptides by these B cells. Further studies [4,5] have
found that IgM-deficient mice develop autoimmune fea-
tures suggestive of lupus, including the production of anti-
dsDNA antibodies. Since a similar autoimmune tendency
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has been reported in human patients deficient for IgA [6],
it is conceivable that immunoglobulins are also instrumen-
tal in self-regulation. Therefore, it appears that we are just
beginning to understand an integrated network of different
immune-cell compartments where B cells seem to be of
more central importance than was previously appreciated.
A consistent finding in lupus is intrinsic B-cell hyperreac-
tivity. Upon stimulation of the B-cell receptor, lupus B cells
show abnormally high Ca influxes followed by higher con-
centrations of inositol triphosphate and tyrosine phospho-
rylated proteins, as compares to B cells from normal
controls [7], indicating a unique, intrinsic abnormality of
B cells in SLE. However, an overwhelming B-cell overac-
tivity induced by signaling through membrane receptors
cannot be excluded. In this context, stimulation via com-
plement receptor 2 has been suggested to contribute to
signaling abnormalities in lupus [8], since the ligand of this
receptor, C3d, was identified to be part of immune com-
plexes in lupus [9].
Anti-dsDNA antibodies present in SLE are generally IgG
with high affinity for antigen, and display somatic mutations
in the immunoglobulin variable regions. These are molecular
characteristics of antibodies arising in an antigen-driven, T-
cell-dependent response. Furthermore, blocking B-cell/T
cell costimulation with CTLA4Ig or anti-CD40 ligand in
murine lupus results in dramatic effects on anti-DNA anti-
body titers, renal disease, and survival [10–14]. Clearly, B-
cell/T-cell cognate interactions are critical in lupus; inhibition
of costimulation is a novel and potentially very useful
approach to the treatment of human autoimmune disease.
BAFF/zTNF and TACI, a novel ligand/receptor
pair
Interactions between tumor necrosis factor (TNF)-like
ligands and their receptors are crucial to the regulation of
the immune response, via induction of apoptosis or by pro-
moting cell survival and proliferation [15]. The recent dis-
covery of interacting molecules belonging to these
ever-growing families has afforded important insights into
normal and pathological immunity, while facilitating the
development of a new approach to therapeutic modulation
of autoimmune disease by blocking a novel pathway of B-
and T-cell interaction.
BAFF (B-cell-activating factor) was identified as a member of
the TNF family in 1999 by several independent research
groups and consequently is alternatively referred to in the lit-
erature as TALL-1, THANK, BlyS, and zTNF4 [16–19]. BAFF
is expressed on dendritic cells, monocytes/macrophages,
and T cells. It quickly became clear that BAFF is a positive
regulator of B-cell function, with effects on cell survival, acti-
vation, and differentiation. Soluble BAFF costimulates B cells
activated by anti-IgM [16] or by IL-4 [20], and may also have
weaker direct stimulatory effects [20].
By means of receptor-cloning methodology, two previ-
ously orphan members of the TNF-receptor superfamily,
known as TACI (transmembrane activator and CAML-
interactor) and BCMA (B-cell-maturation antigen), were
found to be the receptors for BAFF on B cells [21–24].
Soluble receptor (TACI-Ig: a fusion protein of the extracel-
lular domain of the receptor with the Fc portion of an
immunoglobulin molecule) prevented binding of BAFF to
B cells and inhibited its stimulatory effect on human and
murine B cells in vitro [25]. Blocking the interaction of
BAFF receptor with TACI-Ig in immunized mice results in
significantly decreased numbers of antigen-specific IgM
and IgG antibodies. Moreover, treated mice were found to
be devoid of germinal centers [21]. These data and others
suggest that the interaction between BAFF and TACI, in
an analogous fashion to the related costimulatory pair
CD40 ligand/CD40, is crucial for the normal development
of antigen-specific humoral responses. In contrast to mice
treated with TACI-Ig, however, mice deficient in CD40
ligand and CD40 have normal IgM responses, suggesting
that the interaction between BAFF and TACI may occur
earlier in B-cell activation. It is important to note that
soluble TACI also inhibits T-cell-independent responses
[23]. More recent studies have addressed the molecular
mechanisms involved in BAFF binding to its receptor
[21,23,26]. Similar to other members of the TNF-receptor
family that lack a death domain [15], the intracellular
domain of TACI associates with TNF-receptor-associated
factors (TRAF) and activates NFkB and c-Jun NH2 termi-
nal kinase, thus presumably transducing signals for B-cell
proliferation and survival.
BAFF and autoimmunity
The discovery that BAFF mediates a strong signal for
B-cell proliferation and survival led researchers to con-
sider a role for this molecule in diseases characterized by
B-cell hyperactivity. Important confirmation of a possible
role of BAFF in the pathogenesis of autoimmunity came
from transgenic studies. In BAFF-transgenic mice (under
control of a liver specific promotor), Mackay et al [10]
found a significant expansion of the peripheral B-cell com-
partment (spleen and lymph nodes), with mature cells
exhibiting an activated phenotype. Numerous germinal
centers were present without immunization, and the
number of plasma cells was increased. Some but not all
BAFF-transgenic mice displayed marked hyperglobu-
linema, with circulating immune complexes and a positive
rheumatoid factor, high titers of antibodies against single-
stranded and double-stranded DNA, and immunoglobulin
deposition in the kidneys. Similar results were reported by
Khare et al [20], who generated TALL-1 transgenic mice
under the control of a beta actin promoter. The transgenic
mice had marked B-cell hyperplasia and hypergamma-
globulinemia. Furthermore, there was a progressive
increase in serum IgM and IgG anti-dsDNA antibody titers
over time, followed by immune-complex nephritis and renaldysfunction. The serological manifestations and renal
involvement in both BAFF transgenic models are strongly
reminiscent of SLE. Moreover, high serum concentrations
of BAFF were found in two murine models of lupus
(NZB × NZW F1 and MRL-lpr/lpr), with an increase in
serum BAFF concentrations over time paralleling worsen-
ing disease activity [25].
The positive regulatory effects of BAFF on B cells and on T-
cell-dependent humoral responses, the autoimmune pheno-
type of BAFF transgenic mice, and the high levels of BAFF
in lupus-prone mice suggest that blocking the interaction
between BAFF and its receptor with TACI-Ig may be a
useful therapeutic approach in murine lupus [25]. Female
21-week-old B/W mice were treated with TACI-Ig three
times weekly for 5 weeks. Mice treated with a high dose of
TACI-Ig had a markedly delayed onset of proteinuria. Impor-
tantly, treatment also resulted in a meaningful difference in
survival, with 100% of the animals receiving TACI-Ig surviv-
ing to 38 weeks versus only 47% of controls. Although anti-
dsDNA antibody titers did not decline, treated mice
exhibited a decrease in peripheral-blood B cells.
Conclusion
Clearly, we do not yet fully appreciate the myriad immune
defects found in SLE. In this commentary, we discussed
some of the recent experimental approaches to defining
novel roles for B cells and B-cell/T-cell collaboration in the
pathophysiology of SLE. These discoveries have provided
new insights into our understanding of abnormalities in
immune regulation in lupus, and might eventually provide
the opportunity to improve the specificity and effective-
ness of therapeutic approaches to this complex disease.
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